

Dear Sir/Madam,

The Brainstorm Company reached an agreement with the Tel-Aviv Medical Center to conduct a clinical trial with the company's stem cell technology in ALS. The trial is planned to begin recruiting patients (only Israeli residents) in the third quarter of 2017. At the same time, the company and the medical center will try to make this therapy available for ALS patients who are not candidates for the clinical trial within a hospital exempt procedure, which means that interested patients ineligible for the trial will be able to receive it against payment of related costs.

At the moment the hospital and company have asked for permission for this type of treatment from the Ministry of Health, and the permission awaits final decision. In any case, the hospital exempt treatment will not begin before the clinical trial; therefore it is expected to begin also in the second part of the year.

We do not know yet when exactly this therapy will be available at our center, how much it will cost, and which patients will be eligible for it.

Please take also into account that the results shown with this technology indicate a SMALL improvement, and every patient has to make a balanced decision between this small effect and the costs of the treatment and costs and logistics of overseas travel.

Please contact us again in June-July for more information.

Sincerely,

Vivian E Drory, MD, Associate Professor of Neurology Director of Neuromuscular Service,
Tel-Aviv Medical Center 6, Weizmann St, 64239 Tel-Aviv, Israel

Tel: +9723-6973689

Fax: +9723-6974630

E-mail: vdrory@post.tau.ac.il